Request Demo

Last update 08 May 2025

Radiation-induced Rectal Injury

Last update 08 May 2025

Basic Info

Synonyms-

Introduction-

Drugs associated with Radiation-induced Rectal Injury

Montelukast sodium

Target

CysLT

Mechanism

CysLT antagonists

Active Org.

KYORIN Pharmaceutical Co., Ltd. [+6]

Originator Org.

Merck & Co., Inc.

Active Indication

Asthma, Exercise-Induced [+11]

Inactive Indication

Acute asthma [+11]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date20 Feb 1998

Human umbilical cord mesenchymal stem cells(Jiangsu Topcel-KH Pharmaceutical)

Target-

Mechanism

Cell replacements

Active Org.

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.

Originator Org.

Jiangsu Tuohong Kangheng Pharmaceutical Co., Ltd.

Active Indication

Crohn Disease [+3]

Inactive Indication-

Drug Highest PhasePhase 3

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Radiation-induced Rectal Injury

ChiCTR2500099215

/ SuspendedNot ApplicableIIT

Clinical study of the safety of human umbilical cord mesenchymal stem cell exosomes in the treatment of radiation-related rectal lesions

Start Date01 Apr 2025

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

NCT06776029

/ RecruitingPhase 2IIT

A Prospective, Single-Arm Trial of Fecal Microbiota Transplantation for Hemorrhagic Radiation-Induced Rectal Injury

The goal of this single-arm trial is to learn if Fecal Microbiota Transplantation (FMT) works to treat hemorrhagic radiation-induced proctopathy. The main questions it aims to answer are:
* Dose FMT alleviate the symptom of severe rectal bleeding?
* Dose FMT improve the endoscopic findings of proctopathy?
Participants will:
* Take fecal microbiota capsules by 8 sessions over a 12-week period.
* Visit the clinic once every 4 weeks for checkups and tests.
* Keep a diary of their symptoms and the number of times they use other supportive care.

Start Date01 Feb 2025

Sponsor / Collaborator

The Sixth Affiliated Hospital of Sun Yat-Sen University

NCT06776016

/ RecruitingPhase 2IIT

A Prospective, Single-Arm, Single-Center Study of Dietary Supplements in the Treatment of Radiation-Induced Rectal Injury

This clinical study is a prospective, single-arm, single-center trial aimed at assessing the safety and efficacy of tributyrin (TB) as dietary supplements in the treatment of chronic radiation-induced rectal injury (RRI). We hypothesize that these supplements will help improve rectal bleeding symptoms and elevate the quality of life for patients. The study will test whether the supplements can lower the LENT-SOMA scales of rectal bleeding and enhance overall patient health. Efficacy will be evaluated through blood tests and other non-invasive methods, ensuring patient safety and comfort throughout the study.

Start Date15 Jan 2025

Sponsor / Collaborator

The Sixth Affiliated Hospital of Sun Yat-Sen University

100 Clinical Results associated with Radiation-induced Rectal Injury

100 Translational Medicine associated with Radiation-induced Rectal Injury

0 Patents (Medical) associated with Radiation-induced Rectal Injury

249

Literatures (Medical) associated with Radiation-induced Rectal Injury

01 Jun 2025·Clinical Nutrition

Synbiotics protected radiation-induced tissue damage in rectal cancer patients: A controlled trial

Article

Author: Johnson, Louis B ; Fallone de Andrade, Sérgio ; Xu, Jie ; Stene, Christina ; Molin, Göran ; Jeppsson, Bengt ; Thorlacius, Henrik ; Ahrné, Siv ; Palmquist, Ingrid

BACKGROUND & AIMSColorectal cancer (CRC), particularly rectal cancer, often requires neoadjuvant radiotherapy (RT) as part of its treatment plan. Although effective, RT can cause significant gastrointestinal side effects. Because the onset of RT-induced tissue injury can be anticipated, there is an opportunity to apply preventive measures before the damage occurs. This study aimed to assess whether prebiotic and synbiotic interventions could mitigate RT-induced gut injury by modulating the mucosa-associated microbiota, reducing inflammation, and enhancing gut barrier function in patients undergoing RT for rectal cancer.METHODSThirty patients with rectal adenocarcinoma scheduled for preoperative short-term RT (5 × 5 Gy) were divided into three groups: a control group (Ctrl), a prebiotic group (Fiber) receiving oat bran, and a synbiotic group (Synbiotics) receiving oat bran with L. plantarum HEAL19 and blueberry husks. The study products were administered daily for two weeks, starting one week before RT. Blood, faecal, and biopsy samples were collected before and after RT to evaluate inflammatory markers, intestinal permeability, histopathological changes, and mucosa-associated microbiota.RESULTSThe Fiber and Synbiotics groups exhibited a significant reduction in white blood cell counts following RT (p = 0.01 for both), whereas the Ctrl group did not demonstrate a significant change. However, there was no significant difference in the magnitude of change in white blood cell counts among the three groups (p = 0.12). Histopathological analysis revealed that the Synbiotics group had reduced inflammation and fibrosis compared to the Fiber and Ctrl groups. Although RT reduced bacterial diversity overall, the Synbiotics group preserved a greater proportion of bacterial species, experiencing only a 25.1 % reduction compared to a 55.4 % reduction in the Fiber group.CONCLUSIONSynbiotic interventions may protect rectal mucosa by reducing inflammation and modulating mucosa-associated microbiota. The effects were primarily localized to the tissue, reflecting the short-term duration of treatment. While immediate benefits were observed, longer-term interventions should be explored to reduce systemic inflammation.

01 May 2025·Biochemical and Biophysical Research Communications

Formononetin prevents intestinal injury caused by radiotherapy in colorectal cancer mice via the Keap1-Nrf2 signaling pathway

Article

Author: Lou, Jun ; Yu, Qingqing ; Mo, Weixing ; Zhao, Linfang ; Zhang, Lidan ; Zhang, Ke ; Li, Lingdi ; Tang, Rongjun

Radiation-induced intestinal injury (RIII) is a serious complication of radiation therapy. Formononetin (FT) is a methoxy isoflavone with anti-tumor and anti-oxidant properties. This study explored whether FT reduces ROS by activating the Keap1/Nrf2 pathway and thereby protecting against RIII. 30 BABL/C mice were used to construct a colorectal cancer model with CT26 cells and validated the model on day 7. Then, the cancer model mice were divided into 3 groups on day 14 (model control, model, and model + FT) with administration of FT or saline and radiated them on day 21. All samples were collected on day 28. Mechanical intestinal barrier assessed via intestinal absorption function, HE staining, and Claudin-1, Occludin, ZO-1 expression. Apoptosis was measured by TUNEL and cleaved-caspase 3, angiogenesis by CD31, and oxidative stress by NO and ROS levels. Keap1, Nrf2 (cytoplasm) and Nrf2 (nucleus) expression were measured by Western blot. FT treatment enhanced absorption and reduced damage and apoptosis in intestinal tissue. During FT treatment, inhibition of NO and ROS leads to suppression of oxidative stress and promotion of CD31 expression promotes angiogenesis. FT upregulated the expression of nuclear Nrf2 and reduced cytoplasmic Keap1 and Nrf2. FT strengthens mechanical barrier and decreases oxidative stress in intestinal tissue, providing radiation injury protection. Its anti-radiation effect may be through Keap1/Nrf2 pathway activation.

01 Apr 2025·Phytomedicine

Maintained homeostasis: LGYD facilitated the restoration of ISCs following radiation exposure by activating Hes1

Article

Author: Gao, Yue ; Wang, Yuguo ; Wang, Ningning ; Ni, Zhexin ; Zhang, Liangliang ; Yan, Ziqiao ; Zhou, Wei ; Bai, Zhijie ; Chang, Mingyang ; Xia, Tiantian ; Shen, Pan ; Li, Yangshuo ; Yu, Hongyang ; Dou, Yongqi

BACKGROUNDRadiation-induced Intestinal Injury (RIII) affects quality of life in radiotherapy patients; Liangxue Guyuan Yishen Decoction (LGYD) offers protection but requires further study on its mechanism.PURPOSEThe aim of this study was to investigate the heterogeneity of cellular responses in the intestine at a single-cell level following radiation and LGYD treatment.STUDY DESIGNThis study's design includes in vivo and in vitro assessments to evaluate LGYD's effects on intestinal cells post-radiation, targeting survival, recovery, and molecular pathways.METHODSMice were categorized into four groups: LGYD group, NC group, IR group, and Am group. Each group received daily drug administrations. All groups, except for the NC group, were subjected to a single whole-body irradiation at a dose rate of 70 R/min with a source-to-skin distance of 250 cm. Subsequent experiments were conducted following the irradiation, which led to severe survival impairments in the mice.RESULTSOur findings demonstrate that LGYD intervention substantially improves survival rates following lethal doses (8.5 Gy, 70R/min) of whole-body irradiation. Moreover, LGYD expedites the recovery period for intestinal injury on the fifth day after radiation by promoting repair mechanisms within intestinal tissue, with particular focus on mitigating intestinal stem cells (ISCs) damage and immune disorders. Through both in vivo and in vitro experiments, we have discovered that LGYD effectively treats RIII by activating Hes1 transcription factor activity through its key active ingredients in drug-containing serum. This activation further upregulates the downstream Stat3 and Akt gene, thereby facilitating repair processes within intestinal stem cells.CONCLUSIONIn this study, we discovered that LGYD can enhance the downstream expression and phosphorylation pathways of Stat3 and Akt by upregulating the expression of Hes1 gene following high-dose radiation exposure.

News (Medical) associated with Radiation-induced Rectal Injury

14 May 2021

·www.biospace.com

Radiation Proctitis Treatment Market to Grow At 7% CAGR; High Demand for Oral Treatment Options Boosts Growth, Fact.MR

Rising popularity of anti-inflammatory drugs for treating radiation induced rectal bleeding is facilitating radiation proctitis treatment market growth. Fact.MR, New York: As per a study by Fact MR, the global radiation proctitis treatment market is expected to surpass the valuation of US$750 Mn by the end of 2031. Hyperbaric oxygen treatment has yielded promising results during treatment of severe radiation induced symptoms. Research and development in the field of oncology and medicine will escalate the demand for radiation proctitis treatment. According to report published by the World Health Organization (WHO), around 600,000 women are diagnosed with cervical cancer by 2020. That is around 6.5% of all female cancers. Radiotherapy is usually recommended as a main treatment option. Cancer recurrence is also treated by employing radiotherapy. Extensive use of radiation therapy will lead to radiation proctitis boosting the radiation proctitis treatment market growth. “Soaring incidence of cervical cancer and encouragement towards using radiation therapy as treatment option have led to jump in radiation proctitis cases. Market players are constantly working towards developing highly efficient treatment, thus driving the market growth”, said a lead analyst at Fact.MR. Request Sample of the 170-page report on the radiation proctitis treatment market Radiation proctitis treatment market: Key Findings Growing prevalence of prostate cancer and other pelvic malignancies in US has fuelled the demand for radiation proctitis treatment. Surging demand for use of high energy x-ray to treat various forms of cancer in UK will assist in radiation proctitis treatment market growth. High dependence on radiotherapy for cancer treatment and increasing funding towards cancer research in Germany will drive the market growth. Growing customer preference towards minimal invasive and oral therapy using Sulfasalazine and balsalazide will further propel the market growth. Increasing use of microbiotics towards treatment of chronic radiation proctitis will drive the market expansion. Explore 84 tables and 112 figures of the study. Request ToC of the report at Radiation proctitis treatment market – Key Driving Factors Introduction of anti inflammatory drugs for treating severe radiation symptoms and side effects fuels the market growth. Increasing use of hyperbaric oxygen therapy for treatment of severe proctitis boosts the market demand. Soaring demand of radiation therapy in pharmaceutical sector for treating cervical, rectal and prostate cancer boosts market growth. Radiation proctitis treatment market – Key Restraints Expensive radiation proctitis treatment procedure along with grim radiation induced symptoms hinders the market growth. Consistent efforts towards developing alternative treatments for radiation proctitis will impede the market growth in future. Lack of healthcare infrastructure coupled with low awareness regarding the treatment in developing countries hampers the market expansion. Radiation proctitis treatment market – COVID-19 Impact COVID-19 pandemic stressed the global healthcare system to its core. The impact of the pandemic varied on regional basis. Redirection of skilled staff towards COVID patients and reduced funding slowed the radiation proctitis treatment market. Disruption of supply chain led to delay in raw material procurement negatively affecting the market growth. Lockdown led to closure of manufacturing sectors leading to shortage of radiation proctitis treatment equipments further hampering the market sales. Competitive Landscape Some of the leading radiation proctitis treatment manufacturers are Allergan Plc., Amneal Pharmaceuticals Inc., Mylan Inc. (Viatris), Johnson & Johnson (Johnson & Johnson Consumer Inc.), Environmental Tectonics Corporation, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi SA, Pharmaceutical Industries Ltd., Sun , Sechrist Industries Ltd. The market is highly consolidated and is forcing market players towards developing new products to strengthen their foothold. They are also collaborating and doing strategic merger to further their market reach and working towards regulatory approvals from concerned agencies. For instance, Sanofi SA acquired Kiadis Pharma in April 2021 to strengthen its market position in the immuno-oncology sector. Pfizer Inc. collaborated with Myovant Sciences in December 2020 with the mission to develop and commercialize ORGOVYXTM for advanced prostate cancer and gonadotrophin-releasing hormone (GnRH) receptor antagonist to advance women’s health. Get Customization on this Report for Specific Research Solutions More Insights on the radiation proctitis treatment market In its latest report, Fact.MR offers unbiased analysis of the radiation proctitis treatment market. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of indication (Acute Radiation Proctitis Treatment, Chronic Radiation Proctitis Treatment), Therapy (Oral Therapy, Ablative Procedures, Hyperbaric Oxygen Therapy, Formalin, Surgery) across five regions (North America, Latin America, Europe, Asia Pacific, MEA). Explore Fact.MR’s Coverage on the Healthcare Domain Radiation nephropathy treatment and management market: The global radiation nephropathy treatment and management market study published by Fact.MR offers an unbiased analysis of the prominent drivers, opportunities and trends expected to shape future expansion outlook. The report provides a comprehensive assessment on the prominent segments and geographies which are likely to benefit market players in forthcoming years. MRI-guided radiation therapy systems market: Fact. MR’s extensive coverage on the MRI-guided radiation therapy systems market offers in-depth insights about the prominent growth dynamics that are likely to aid expansion of growth prospects in the near future. Data has been presented in the form of key segments across prominent geographies, along with important information concerning key manufacturers operating within the industry. Peritoneal cancer treatment market: A recent study by Fact.MR on the peritoneal cancer treatment market offers a 10-year forecast analysis for the period 2018 to 2028. The study analyzes key trends that are currently determining the growth of the market. This report covers key dynamics, including drivers, restraints, and opportunities for leading market players along with key stakeholders and emerging players. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Mahendra Singh US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: sales@factmr.com Follow Us: LinkedIn | Twitter Source: Fact.MR

Radiation TherapyAcquisitionCollaborate

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Radiation-induced Rectal Injury

Basic Info

Related

Analysis